Document is current
Any future updates will be listed below
-
Authors
Sierksma, Annerieke
Lu, Ashley
Salta, Evgenia
Vanden Eynden, Elke
Callaerts-Vegh, Zsuzsanna
D’Hooge, Rudi
Blum, David
Buée, Luc
Fiers, Mark
De Strooper, Bart
-
Funding
Funding for this research was provided by:
Alzheimer Research Foundation (P#16017)
Agence Nationale de la Recherche (ANR-16-COEN-0007)
Leuven Universitair Fonds (Opening the Future Campaign)
FP7 Ideas: European Research Council (ERC-2010-AG_268675)
Vlaams Initiatief voor Netwerken voor Dementie Onderzoek (Strategic Basic Research Grant 135043)
Vlaams Instituut voor Biotechnologie
Vlaamse Overheid & KU Leuven (Methusalem grant)
FWO (12A5316N)
Alzheimer's Association (AARF-16-442853)
Geneeskundige Stichting Koningin Elisabeth
- License Information
-
More Information
Article History
Received: 13 April 2018
Accepted: 27 September 2018
First Online: 12 October 2018
Ethics approval and consent to participate
: All animal experiments were conducted according to protocols approved by the local Ethical Committee of Laboratory Animals of the KU Leuven (governmental licence LA1210591, ECD project number P202–2013) following governmental and EU guidelines.Hippocampal tissue samples were obtained from the London Neurodegenerative Diseases Brain Bank and collected in accordance to British legislation and their ethical board []. The human study was evaluated and approved by the ethical committees of Leuven University and UZ Leuven [].
: Not applicable.
: BDS is consultant for Janssen Pharmaceutica. LB is consultant for Servier and Remynd. He receives research funding from UCB Pharma, but not for the work presented in the current manuscript. AS, AL, ES, EVE, ZCV, RDH, DB and MF report no biomedical financial interests or potential conflicts of interest.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
